Abstract:The study of large prospective collections of plasma samples from women prior to the development of breast cancer has firmly established certain sex steroids as being significantly associated with risk. The strongest associations have been found in postmenopausal women in whom the within person variability of most hormones is markedly reduced but some positive associations have also been seen in premenopausal women. Plasma estrogens show the strongest correlations with risk and these are strengthened by measurement or calculation of the proportion of estradiol that circulates free of sex hormone binding globulin (SHBG), consistent with this being the most active fraction. The relationships have been reported to potentially explain virtually all of the association of breast cancer with body mass index in postmenopausal women; this is likely to be due to non-ovarian estrogen synthesis being prominent in subcutaneous fat. These strong relationships have led to plasma and urine estrogen levels being used as intermediate end-points in the search for genes that affect breast cancer risk via their role in steroid disposition. Plasma androgen levels also show a relationship with breast cancer risk that is weakened but not eliminated by 'correction' for estrogen levels. This has been argued to be evidence of the local production of estrogens being important in the etiology of breast cancer. Given that plasma steroid levels do not correlate closely with mammographic density, which is strongly associated with risk, the opportunity exists to combine the two factors in assessing breast cancer risk but the low availability of suitable estrogen assays is a major impediment to this. In established breast cancer, plasma estrogens have been found to correlate with gene expression of estrogen dependent genes and the expression of these varies across the menstrual cycle of premenopausal women. There is infrequently a need for routine measurement of plasma estrogen levels but it has been important in the comparative pharmacology and dose-related effectiveness of aromatase inhibitors. Measurement may be needed to identify residual ovarian function in women who have amenorrhea subsequent to cytotoxic chemotherapy indicating their unsuitability for aromatase inhibitor treatment. Use of highly sensitive assays has also revealed that the association between BMI and plasma estrogen levels persists in patients on 3rd generation aromatase inhibitors and that measurable increments in plasma estrogen levels occur with some vaginal estrogen preparations that are of concern in relation to treatment efficacy.

Ornithine and breast cancer: a matched case–control study

A case-control study of arsenic exposure with the risk of primary ovarian insufficiency in women

Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics.

The Association Between N-nitrosamines Exposure and Lipid Metabolism in the High Incidence Area of Esophageal Cancer: A Case-Control Analysis

Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection

Circulating Carnitine Levels and Breast Cancer: A Matched Retrospective Case-Control Study

Appraising the Role of Circulating Concentrations of Micro-Nutrients in Epithelial Ovarian Cancer Risk: A Mendelian Randomization Analysis

Relationship Between the N-3 Index, Serum Metabolites and Breast Cancer Risk.

Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never-smoking women

Abstract P2-10-09: Oxysterol profiling in breast adipose tissue identifies brassicasterol and 24-hydroxycholesterol as breast cancer risk predictors

Premenopausal serum androgens and breast cancer risk: a nested case-control study

The Correlation Between Potential “Anti- Cancer” Trace Elements and the Risk of Breast Cancer: A Case-Control Study in a Chinese Population

Sex hormones and breast cancer risk and prognosis

ORNITHINE DECARBOXYLASE AND PUTRISCINE IN PATIENTS WITH GASTROINTESTINAL CANCER

Polymorphisms in the CYP19A1 (Aromatase) Gene and Endometrial Cancer Risk in Chinese Women

Association of Sulfotransferase Sult1a1 with Breast Cancer Risk: A Meta-Analysis of Case-Control Studies with Subgroups of Ethnic and Menopausal Statue

Urinary heavy metals and overall survival of advanced high-grade serous ovarian cancer: A nested case-control study in China

Urinary Excretion of Phytoestrogens and Risk of Breast Cancer among Chinese Women in Shanghai.

Association Between SNPs in the One-Carbon Metabolism Pathway and the Risk of Female Breast Cancer in a Chinese Population

The association between two polymorphisms of eNOS and breast cancer risk: a meta-analysis

Correlation of blood sex steroid hormones with body size, body fat distribution, and other known risk factors for breast cancer in post-menopausal Chinese women